Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

6.0%

3 terminated/withdrawn out of 50 trials

Success Rate

89.7%

+3.1% vs industry average

Late-Stage Pipeline

42%

21 trials in Phase 3/4

Results Transparency

4%

1 of 26 completed trials have results

Key Signals

8 recruiting1 with results

Enrollment Performance

Analytics

Phase 3
18(43.9%)
N/A
9(22.0%)
Phase 2
8(19.5%)
Phase 1
3(7.3%)
Phase 4
3(7.3%)
41Total
Phase 3(18)
N/A(9)
Phase 2(8)
Phase 1(3)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (50)

Showing 20 of 50 trials
NCT04043494Phase 3Recruiting

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Role: collaborator

NCT03206671Phase 3Active Not Recruiting

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Role: collaborator

NCT05582902Active Not Recruiting

Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients

Role: collaborator

NCT02684708Phase 3Completed

Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

Role: collaborator

NCT04495088Phase 3Recruiting

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

Role: collaborator

NCT05212012Phase 1Active Not Recruiting

D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer

Role: collaborator

NCT07150598Not Yet Recruiting

Immune-Marker Platform for Patients With Advanced Lung Cancer

Role: collaborator

NCT00453674Recruiting

German Adrenocortical Carcinoma Registry

Role: collaborator

NCT00669266Recruiting

Adrenal Tumors - Pathogenesis and Therapy

Role: collaborator

NCT00457587Active Not Recruiting

Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

Role: collaborator

NCT06980740Recruiting

Video-Tumorboard PLUS

Role: collaborator

NCT03643276Phase 3Recruiting

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Role: collaborator

NCT02170090Phase 3Active Not Recruiting

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

Role: collaborator

NCT04469699Phase 2Terminated

Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma

Role: collaborator

NCT04375605Phase 3Active Not Recruiting

Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

Role: collaborator

NCT04447352Phase 3Recruiting

HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)

Role: collaborator

NCT06019130Phase 2Recruiting

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

Role: collaborator

NCT01088750Phase 4Completed

Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Role: collaborator

NCT02363374Phase 2Completed

Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer

Role: collaborator

NCT05365269Not ApplicableCompleted

Proactive Automatized Lifestyle Intervention

Role: collaborator